A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:11
|
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Biomarkers in chimeric antigen receptor T-cell therapy
    Kong, Weimin
    Lacey, Simon F.
    Melenhorst, Jan Joseph
    Fraietta, Joseph A.
    BIOMARKERS IN MEDICINE, 2018, 12 (05) : 415 - 418
  • [22] Chimeric antigen receptor T-cell therapy for glioblastoma
    Rodriguez, Analiz
    Brown, Christine
    Badie, Behnam
    TRANSLATIONAL RESEARCH, 2017, 187 : 93 - 102
  • [23] Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
    Choi, Taewoong
    Kang, Yubin
    PHARMACOLOGY & THERAPEUTICS, 2022, 232
  • [24] Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
    Feldman, Lisa
    Brown, Christine
    Badie, Behnam
    NEUROMOLECULAR MEDICINE, 2022, 24 (01) : 35 - 40
  • [25] Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
    Lisa Feldman
    Christine Brown
    Behnam Badie
    NeuroMolecular Medicine, 2022, 24 : 35 - 40
  • [26] A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
    Atrash, Shebli
    Moyo, Tamara K.
    ONCOTARGETS AND THERAPY, 2021, 14 : 2185 - 2201
  • [27] Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma-Recent Advances
    Kowalczyk, Adrian
    Zarychta, Julia
    Marszolek, Anna
    Zawitkowska, Joanna
    Lejman, Monika
    CANCERS, 2024, 16 (03)
  • [28] Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy
    Adhikarla, Vikram
    Awuah, Dennis
    Caserta, Enrico
    Minnix, Megan
    Kuznetsov, Maxim
    Krishnan, Amrita
    Wong, Jefferey Y. C.
    Shively, John E.
    Wang, Xiuli
    Pichiorri, Flavia
    Rockne, Russell C.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [29] Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
    Garg, Swati
    Ni, Wei
    Griffin, James D.
    Sattler, Martin
    HEMATOLOGY REPORTS, 2023, 15 (04) : 608 - 626
  • [30] Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
    Xu, Caili
    Ju, Dianwen
    Zhang, Xuyao
    ANTIBODY THERAPEUTICS, 2022, 5 (01) : 73 - 83